Lenvatinib Mesylate

CHEMBL2105704 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
523.0 g/mol
LogP
Phase
4

The mesylate salt form of lenvatinib, a multi-kinase inhibitor approved for thyroid and liver cancers. It is the pharmaceutical form used in the marketed medication.

น้ำหนักโมเลกุล

523.0000 g/mol

TPSA

178.00 Ų

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O

InChI

InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

Molecular Formula

C22H23ClN4O7S

HBD / HBA

4 / 8

พันธะที่หมุนได้

6

อะตอมหนัก

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The mesylate salt form of lenvatinib, a multi-kinase inhibitor approved for thyroid and liver cancers. It is the pharmaceutical form used in the marketed medication.

Yes, Lenvatinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105704. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11237762. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.